title: Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The KOGENATE Study Group.
abstract: Fifty-eight previously treated haemophilic subjects were treated exclusively with the recombinant FVIII (rFVIII-KOGENATE) produced by Bayer Corporation (Berkeley, CA) in an international multicentre prospective study of more than 5 years duration. Fifty-four of the 58 had severe haemophilia (< 2% FVIII) and four had moderate haemophilia (2-5% FVIII); 23/58 (40%) were seropositive for HIV, while 35/58 (60%) were HIV seronegative. Patients were monitored for safety and efficacy over a median period of 4.7 years (range 0.9-5.9 years) and received 17 922 infusions totalling 25.7 million units of rFVIII. Of 7107 bleeding episodes reported in home diaries, 5831 (82%) required only one treatment with rVIII. Twenty-five invasive surgical procedures in 17 patients, including eight joint replacements, were successfully accomplished and 13 serious bleeding episodes in eight patients were successfully treated. FVIII recovery performed on 885 occasions using 39 different lots of rFVIII showed mean incremental recovery of 2.48% IU-1 kg-1 (+/- 0.64). Adverse events were associated with 42 infusions (0.2%); none caused discontinuation of therapy. Immunological parameters remained stable in HIV-seronegative subjects treated with rFVIII; a small decrease in CD4 counts was noted in HIV-seropositive individuals (mean - 37.2 cells mm-3 yr-1). No de novo formation of inhibitors to FVIII was noted; and no clinical allergic reactions occurred to murine or hamster proteins. These conclusions from the longest monitored safety study ever performed for a haemophilia treatment product (with more than 5 years of observation) confirm previous interim study reports that rFVIII is well tolerated over the long-term, has biological activity comparable to that of plasma-derived FVIII, and is safe and efficacious for the treatment of haemophilia A.
authors.affiliation: Department of Medicine, Mt. Sinai School of Medicine, New York, NY, USA.
authors.forename: S
authors.initials: S
authors.lastname: Seremetis
authors.forename: J M
authors.initials: JM
authors.lastname: Lusher
authors.forename: C F
authors.initials: CF
authors.lastname: Abildgaard
authors.forename: C K
authors.initials: CK
authors.lastname: Kasper
authors.forename: R
authors.initials: R
authors.lastname: Allred
authors.forename: D
authors.initials: D
authors.lastname: Hurst
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000917:Antibody Formation; D002648:Child; D002675:Child, Preschool; D006224:Cricetinae; D004274:DNA, Recombinant / Q000235:genetics*; D005169:Factor VIII / Q000235:genetics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006679:HIV Seropositivity; D006467:Hemophilia A / Q000188:drug therapy* / Q000378:metabolism; D006699:Home Care Services; D006801:Humans; D007111:Immunity, Cellular; D007223:Infant; D051379:Mice; D008875:Middle Aged; D015166:Monitoring, Immunologic; D011994:Recombinant Proteins / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D004274:DNA, Recombinant; D011994:Recombinant Proteins; D005169:Factor VIII